|
Company Profile
Essentys AB is an innovative biotech
company developing therapeutics for the treatment and prevention of diseases
in the elderly.
The Company is currently focused on the development of its lead product ES 1 in osteoporosis, in which
proof of concept has been obtained in clinical phase II studies. ES 1
constitutes a completely new approach to the treatment and prevention of
osteoporosis. The data suggest that ES 1 has an anabolic effect on collagen
(the main constituent of the organic structure of bone), potentially
resulting in stronger bone. ES 1 is expected to have an excellent safety
profile thereby making long-term use possible. Essentys envisages the use of
ES 1 in
a broad target group, either as a stand-alone therapy or in combination with
other forms of treatment.
The clinical results show efficacy of ES 1 in osteoporosis through a significant
increase in BMD (Bone Mineral Density) and a positive effect on bone turnover
markers. The data have been presented at the American Society of Bone and
Mineral Research (ASBMR). The study was conducted in compliance with Good
Clinical Practice (cGCP) and Good Manufacturing Practice (cGMP).
Essentys is seeking a licensing partner for the further development of ES 1 in osteoporosis.
|
